🧬 WHAT IS RETATRUTIDE?
Retatrutide is an investigational triple receptor agonist being studied in metabolic research.
It targets three receptor systems:
GIP + GLP-1 + glucagon
That triple-receptor design is what separates retatrutide from single- or dual-pathway incretin medicines.
Researchers are studying how simultaneous signaling through these pathways affects body weight, appetite, glucose regulation, energy balance, and other cardiometabolic measures.
Retatrutide has progressed into large human clinical trials, but it remains an investigational drug and is not an FDA-approved medicine as of this article’s publication.
In simple terms: GLP-1 and GIP are part of the metabolic-signaling story, while glucagon adds a third pathway for researchers to investigate.
Stay curious, research friends. 🧬